A new 40-week randomized trial found that resistance training did not stop weight loss from tirzepatide. It changed what happened to lean tissue and muscle strength. GLP-1 and related incretin drugs have changed obesity treatment. Tirzepatide can produce substantial reductions in body weight and fat mass. But there has been an important question hanging over these medications: What happens to lean tissue and muscle function during rapid weight loss? A new randomized controlled trial published in Nature Medicine provides one of the clearest answers yet. The study included 120 adults with overweight or obesity. Everyone received tirzepatide for 40 weeks. Then the participants were divided into two groups. One group continued their usual activities. The other completed supervised resistance training three times per week. Both groups lost roughly the same amount of body weight. Both groups lost substantial amounts of fat. But when researchers measured lean tissue and strength, the results were dramatically different. The headline is simple: Weight loss was similar. Strength was not. The First Randomized Trial of Its Kind According to the researchers, this was the first randomized controlled trial designed to test whether resistance exercise could help manage losses of lean tissue and muscle function during treatment with tirzepatide. The study is known as the: T-REx Trial Participants were: - Between approximately 50 and 70 years old - Overweight or obese - Initially sedentary - Men and postmenopausal women - Treated with tirzepatide for 40 weeks A total of 120 participants entered the trial. They were randomized into: Tirzepatide only Participants continued their usual activities while receiving tirzepatide. Tirzepatide plus resistance exercise Participants received tirzepatide and completed three supervised resistance training sessions each week. The exercise program was progressive and lasted for the entire 40-week intervention. Importantly, adherence was extremely high.

New FlAsH-ID technology uses a tiny peptide tag, green light, and proximity labeling to study what proteins are doing inside living cells Scientists have developed a new method for studying protein interactions inside living cells using something surprisingly small: A six amino acid peptide tag. The technology is called FlAsH-ID and was described in a new study published in Nature Chemical Biology on November 11, 2026. At first glance, this may sound like another highly technical molecular biology tool with little relevance outside a laboratory. But the underlying problem it addresses is important. Scientists often want to answer questions like: Which proteins interact with this protein? Where does a protein move inside a cell? What changes when a cell receives a stimulus? Which molecular machinery is physically close to a protein of interest? Answering those questions inside a living cell is difficult. And one of the biggest problems with existing methods is size. Many proximity labeling technologies require researchers to attach a relatively large enzyme to the protein they want to study. That large addition can potentially change how the protein behaves. The new FlAsH-ID method takes a different approach. Instead of attaching a protein-sized labeling enzyme, researchers inserted a tiny six amino acid tetracysteine tag. The tag is only: CCPGCC Researchers then used a dye called FlAsH to locate that tiny peptide sequence. When exposed to light, the system generates highly localized chemical activity that labels nearby proteins. Those labeled proteins can then be identified using techniques such as mass spectrometry. The result is essentially a new way to create a molecular map of a protein's neighborhood inside a living cell. And importantly, the researchers showed that the tiny tag was less disruptive than many larger proximity labeling systems when studying a functionally sensitive protein in primary T cells. What Is Proximity Labeling? To understand why this matters, imagine you want to know who a particular person is interacting with at a crowded event.

New Phase 3 research suggests retatrutide could substantially reduce obstructive sleep apnea severity in adults with obesity or overweight Sleep apnea is one of the most common complications associated with obesity. And for many people, the standard treatment is not a tablet or a weekly injection. It is a machine. Continuous positive airway pressure, commonly called CPAP, works by helping keep the airway open during sleep. For many patients, it can be highly effective. But CPAP does not directly address one of the major drivers of obstructive sleep apnea in many people: excess body weight and the anatomical and metabolic factors associated with it. That is why new research involving retatrutide is attracting so much attention. In newly published Phase 3 trials, one retatrutide group experienced an average reduction of 34.3 apnea and hypopnea events per hour of sleep over 80 weeks. The placebo group also improved. But its reduction was approximately 9.9 events per hour. That means the difference between retatrutide and placebo was substantial. And for people who understand what an apnea hypopnea index actually measures, these are numbers worth paying attention to. However, there are several important caveats. Retatrutide is still an investigational medication. It is not currently an FDA approved treatment for obstructive sleep apnea. And a reduction in sleep apnea events does not mean that every person taking retatrutide can throw away their CPAP machine. Here is what the research actually showed. First, What Does “34 Fewer Events Per Hour” Actually Mean? The key measurement used in sleep apnea research is called the apnea hypopnea index, or AHI. AHI measures the average number of: - Apneas - Hypopneas that occur during each hour of sleep. An apnea generally refers to a substantial or complete interruption in breathing during sleep. A hypopnea is a partial reduction in airflow associated with physiological consequences defined by sleep study criteria.

Starting January 1, 2027, buying certain supplements in California could become a little more complicated for young consumers. And yes, this includes products that may contain one of the most researched supplements in the fitness industry: creatine. California Governor Gavin Newsom signed Assembly Bill 2030 into law on September 28, 2026. The law restricts the sale of certain over the counter diet pills and dietary supplements marketed for weight loss or muscle building to people under the age of 18. That distinction matters. Despite headlines suggesting that everyone in California will suddenly need to show identification to buy a tub of creatine, the reality is more complicated. The law does not create a blanket ban on creatine. Instead, it focuses heavily on how a product is labeled, marketed, or otherwise represented. Still, that raises a much bigger question: Should a highly researched supplement such as creatine potentially end up in the same regulatory category as questionable fat burners and aggressively marketed weight loss products simply because of how it is advertised? That is where this debate becomes interesting. What Does California's New Law Actually Do? California's AB 2030 takes effect on January 1, 2027. The law prohibits retailers from selling covered over the counter diet pills and dietary supplements for weight loss or muscle building to consumers under 18. Products may fall within the law's scope when they are labeled, marketed, or otherwise represented as helping someone lose weight or build muscle. Importantly, the law does not simply publish a list saying: Creatine is banned for minors. Instead, the language creates a category based largely on marketing and representation. Creatine is specifically relevant because the legislation allows consideration of ingredients including: - Creatine - Green tea extract - Raspberry ketone - Garcinia cambogia - Green coffee bean extract But the presence of an ingredient does not necessarily mean every product containing that ingredient is automatically treated identically. The marketing and purpose of the product are central to how the law operates.

TH9507 is an interesting compound in growth hormone research because its design is relatively simple. Unlike many peptide analogues that contain multiple substituted amino acids or major structural changes, TH9507 remains very close to the body's natural growth hormone-releasing hormone, or GHRH. In fact, the molecule is based on the complete 44-amino-acid sequence of human GHRH with one important modification at the beginning of the peptide. That small modification may make a major difference to how long the molecule survives before being broken down. But understanding TH9507 requires separating three different things: 1. What its structure was designed to accomplish. 2. What laboratory and animal studies have actually demonstrated. 3. What has and has not been established in humans. That distinction is especially important in the growth hormone peptide space, where mechanistic findings are often presented online as though they automatically prove broader clinical benefits. They do not. What Is TH9507? TH9507 is a synthetic analogue of human GHRH(1-44)-NH2. Its structure retains the full 44-amino-acid sequence of human growth hormone-releasing hormone, but a trans-3-hexenoic acid group is attached to the peptide's N-terminal tyrosine. Apart from that modification, the molecule closely resembles native human GHRH. GHRH is naturally produced in the hypothalamus and plays a role in regulating the growth hormone axis. Its primary target is the growth hormone-releasing hormone receptor, or GHRHR, which is found on pituitary somatotroph cells. When GHRH activates this receptor, the receptor signals through a G-protein pathway known as Gs. This increases intracellular cyclic AMP, or cAMP, which contributes to growth hormone synthesis and release. Growth hormone then has downstream effects, including stimulation of pathways associated with IGF-1 production. The basic pathway can therefore be simplified as: Hypothalamic GHRH → GHRH receptor → intracellular cAMP signalling → growth hormone release → downstream IGF-1 signalling